Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
ID: PAS-22-197Type: BOTH
Overview

Topic

Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: STTRPhase: BOTHYear: 2022

Topic Link

https://www.sbir.gov/node/2230637

Additional Information

https://grants.nih.gov/grants/guide/PA-files/PAS-22-197.html
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for advancing research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) through their Small Business Technology Transfer (STTR) program. The goal of this funding opportunity is to encourage research and commercialization of novel therapies, devices, products, and healthcare programs to prevent the onset of AD/ADRD and reduce the burden on individuals, families, and society. The research areas of interest include prevention, diagnosis, treatment, care, tools, and technology. Examples of specific topics include behavioral interventions, diagnostic screening tests, drug development, in-home technologies, and genetic analysis tools. The solicitation is open until September 6, 2025, and multiple application due dates are provided. For more information and to apply, visit the SBIR topic link here and the solicitation agency URL here.

    Files
    No associated files provided.
    Similar Opportunities
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for advancing research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD). The goal of this solicitation is to encourage research and commercialization of novel therapies, devices, products, and healthcare programs to prevent the onset of AD/ADRD and reduce the burden on individuals, families, and society. The research areas of interest include prevention, diagnosis, treatment, care, tools, and technology. Examples of specific topics include behavioral interventions, diagnostic screening tests, drug development, in-home technologies, and educational training programs. The solicitation is open for applications until September 6, 2025, and the funding will be provided through the Small Business Technology Transfer (STTR) program. For more information and to submit a proposal, visit the grants.gov website or the National Institutes of Health's solicitation page.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for advancing research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) through their Small Business Innovation Research (SBIR) program. The goal of this funding opportunity is to encourage research and commercialization of novel therapies, devices, products, and healthcare programs to prevent the onset of AD/ADRD and reduce the burden on individuals, families, and society. The research areas of interest include prevention, diagnosis, treatment, care, tools, and technology. Examples of specific topics include behavioral interventions, diagnostic screening tests, drug development, in-home technologies, and tools for monitoring cognitive function. The solicitation is open until September 8, 2025, with multiple application due dates throughout the year. More information can be found on the grants.gov and NIH websites.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for advancing research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) through their Small Business Innovation Research (SBIR) program. The goal of this funding opportunity is to encourage research and commercialization of novel therapies, devices, products, and healthcare programs to prevent the onset of AD/ADRD and reduce the burden on individuals, families, and society. The research areas of interest include prevention, diagnosis, treatment, care, tools, and technology. Examples of specific topics include behavioral interventions, diagnostic screening tests, drug development, in-home technologies, and tools for monitoring cognitive function. The solicitation is open until September 8, 2025, with multiple application due dates throughout the year. More information can be found on the grants.gov website.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required). This solicitation aims to support small business concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require federal regulatory approval or bring complex research tools to market. The funding opportunity is open until September 6, 2026. For more information and to apply, visit the solicitation agency URL: link.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required). This solicitation aims to support small business concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require federal regulatory approval or bring complex research tools to market. The funding opportunity is open until September 6, 2026. For more information and to apply, visit the solicitation agency URL: link.
    NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required). This solicitation aims to support Small Business Concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require Federal regulatory approval or bring complex research tools to market. The solicitation is open until September 6, 2026, and more information can be found at the provided links.
    NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required) topic. This solicitation aims to support small business concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require federal regulatory approval or bring complex research tools to market. The solicitation is open until September 6, 2026, and more information can be found at the provided links.
    Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of technologies to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder. The goal is to fill the service gaps that government and the medical community cannot address alone. The technologies should focus on reducing costs, time, and/or increasing access in addressing housing instability, non-medical transportation, food insecurity, utility needs, and personal safety. The products should provide feasible and accessible opportunities for end-users to improve their health-related social needs and SUD outcomes. The solicitation is open for Phase I and Phase II applications, including Fast-Track applications. The application due date is March 13th of each year, starting in 2024. For more information, visit the solicitation link.
    Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of technologies to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder. The purpose of this funding opportunity is to support small business concerns in developing technologies for commercialization that can fill the service gaps in addressing SUD. The research objectives include developing products that reduce costs, time, and increase access in addressing health-related social needs such as housing instability, non-medical transportation, food insecurity, utility needs, and personal safety. The technologies can include physical devices, digital services, software, or non-physical/non-tangible products. The funding opportunity is open for applications until March 14, 2026, and offers both Phase I and Phase II funding options. Phase I focuses on establishing technical merit and feasibility, while Phase II aims to advance technologies towards commercialization. Applicants are encouraged to review the guidelines and adhere to the requirements applicable to their research.
    Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the late-stage translation of biomedical and behavioral research results in arthritis and musculoskeletal and skin diseases from academic/non-profit labs to the marketplace. This Small Business Innovation Research (SBIR) grant opportunity aims to support the development of diagnostic tools, prevention tools, and treatments for these diseases. The focus is on moving lab technologies towards commercial dissemination through partnerships and close collaboration between small businesses and the original developers of the technologies. The research objectives include late-stage pre-clinical studies on technology or therapy feasibility, as well as studies required for regulatory approval before clinical testing. Clinical trials are excluded from this opportunity. The research topics of interest include the development of therapies, innovative drug delivery strategies, biomarker studies, outcome measures and methodologies, and 3D human tissue models. Collaboration between academic/non-profit labs and small businesses is encouraged, with the academic/non-profit labs performing a portion of the project. The proposal should include milestones with quantitative success criteria to measure the progress and efficacy of the project. Applications that do not originate from academic/non-profit labs or propose intervention studies are not responsive to this opportunity. The grant is open for applications until September 6, 2025. For more information, visit the solicitation agency URL: link.